Ocular Therapeutix (OCUL) Earnings Date & Reports

Key Takeaways

• Ocular Therapeutix reported third-quarter 2026 revenue of $12.87 million, an 11.5% decline from $14.54 million a year earlier and below consensus estimates.
• Net loss widened to $94.78 million from $69.42 million in the prior-year period, with a loss of $0.42 per share that missed analyst expectations of roughly $0.36.
• Higher research and development (R&D) spending and pre-commercial investments drove the wider loss as the company advances AXPAXLI toward a New Drug Application (NDA) filing planned for the fourth quarter of 2026.
• Management shifted the SOL-R Phase 3 trial's primary endpoint from week 56 to week 40 and now expects topline results in the first quarter of 2028.
• Cash and equivalents declined to about $530.6 million, though management reiterated its operating runway guidance into 2028.
• Shares fell roughly 7% immediately following the report.
• For more context on the company's latest developments, visit its Major News and Today's Price Move pages, review analyst Price Targets, and check the Forecast page.
• Explore Trending AI Robots to see how AI-driven strategies are approaching the market.

Earnings Context and Why It Matters

Ocular Therapeutix is an ophthalmology-focused biopharmaceutical company whose investment case centers less on its commercial product, DEXTENZA, and more on AXPAXLI (also known as OTX-TKI), an investigational sustained-release treatment for wet age-related macular degeneration (AMD). The third quarter matters because it arrives just ahead of a planned fourth-quarter NDA submission supported by positive Phase 3 SOL-1 data. While the headline revenue and earnings misses reflect rising development costs, investors are watching more closely for updates on regulatory alignment, the SOL-R trial timeline, and cash runway. These factors, rather than the quarter's financial shortfall, are likely to shape sentiment around the stock.

Reported Results

For the third quarter ended September 30, 2026, Ocular Therapeutix reported revenue of $12.87 million, down 11.5% from $14.54 million in the same period a year ago and below consensus estimates of approximately $13.9 million. Net loss widened to $94.78 million from $69.42 million a year earlier. Basic and diluted loss per share (EPS) was $0.42, compared with $0.38 in the prior-year quarter, and missed analyst expectations of roughly $0.36.

The wider loss was driven primarily by higher spending. R&D expenses rose to about $74.8 million from $52.4 million as enrollment accelerated across the HELIOS-3 and SOL-X studies. Selling and marketing expenses reached approximately $15.7 million, reflecting pre-launch hiring, while general and administrative (G&A) expenses totaled about $18.8 million. Cash and equivalents declined to roughly $530.6 million, and management maintained its runway guidance into 2028.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is intended to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, allowing investors to narrow the investable universe to opportunities that match their criteria. Explore the AI Screener to see how it can support your research process.

Market Reaction and Investor Sentiment

Ocular Therapeutix shares traded lower immediately after the report, falling roughly 7% as investors weighed the wider-than-expected loss and the extended SOL-R timeline against progress on the AXPAXLI regulatory path. The market reaction suggests that, while the financial miss was notable, the more consequential development was the shift in the SOL-R primary endpoint from week 56 to week 40 and the corresponding move of topline results to the first quarter of 2028, later than some investors had anticipated. Sentiment remains tied to the company's ability to execute on its near-term NDA submission, which management reiterated remains on track for the fourth quarter of 2026 following a positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA).

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the planned fourth-quarter 2026 NDA submission for AXPAXLI in wet AMD. Management has said the filing will be supported by SOL-1 Week 52 efficacy data and a combined safety database of more than 300 patients with at least one year of follow-up, and that the company will pursue the 505(b)(2) regulatory pathway, which could shorten review time by up to 60 days compared with a traditional new molecular entity filing.

Investors should also monitor the SOL-R trial following the endpoint change. By moving the primary efficacy endpoint from week 56 to week 40, the company aims to preserve the statistical integrity of the study ahead of a planned interim safety analysis. The trial will remain masked through week 96, with topline non-inferiority data against aflibercept now expected in the first quarter of 2028.

Finally, watch cash and spending trends. Cash declined to about $530.6 million as R&D and commercial-readiness costs rose, and while management reiterated its runway guidance into 2028, that projection excludes the full cost of scaling manufacturing and the commercial organization. Continued enrollment progress in HELIOS-3 and SOL-X, along with any updates on the competitive landscape for wet AMD treatments, will be important signals for how the AXPAXLI opportunity develops.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations